Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Dormant
Current status date:
2023-07-13
Original market date: See footnote 1
2021-01-25
Product name:
VPI-AMIKACIN
Description:
SINGLE USE VIAL
DIN:
02506599
Product Monograph/Veterinary Labelling:
Date:
2020-10-13
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
VPI PHARMACEUTICALS INC
16667 Hymus Boulevard
Kirkland
Quebec
Canada
H9H 4R9
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Intramuscular , Intravenous
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
08:12.02
Anatomical Therapeutic Chemical (ATC): See footnote 4
J01GB06 AMIKACIN
Active ingredient group (AIG) number:See footnote5
0111922001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| AMIKACIN (AMIKACIN SULFATE) | 500 MG / 2 ML |